Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS: Patients were enrolled after they had undergone a coronary stent procedure in which a drug-eluting stent was placed. After 12 months of treatment with a thienopyridine drug (clopidogrel or prasugrel) and aspirin, patients were randomly assigned to continue receiving thienopyridine treatment or to receive placebo for another 18 months; all patients continued receiving aspirin. The coprimary efficacy end points were stent thrombosis and major adverse cardiovascular and cerebrovascular events (a composite of death, myocardial infarction, or stroke) during the period from 12 to 30 months. The primary safety end point was moderate or severe bleeding. RESULTS: A total of 9961 patients were randomly assigned to continue thienopyridine treatment or to receive placebo. Continued treatment with thienopyridine, as compared with placebo, reduced the rates of stent thrombosis (0.4% vs. 1.4%; hazard ratio, 0.29 [95% confidence interval {CI}, 0.17 to 0.48]; P<0.001) and major adverse cardiovascular and cerebrovascular events (4.3% vs. 5.9%; hazard ratio, 0.71 [95% CI, 0.59 to 0.85]; P<0.001). The rate of myocardial infarction was lower with thienopyridine treatment than with placebo (2.1% vs. 4.1%; hazard ratio, 0.47; P<0.001). The rate of death from any cause was 2.0% in the group that continued thienopyridine therapy and 1.5% in the placebo group (hazard ratio, 1.36 [95% CI, 1.00 to 1.85]; P=0.05). The rate of moderate or severe bleeding was increased with continued thienopyridine treatment (2.5% vs. 1.6%, P=0.001). An elevated risk of stent thrombosis and myocardial infarction was observed in both groups during the 3 months after discontinuation of thienopyridine treatment. CONCLUSIONS: Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding. (Funded by a consortium of eight device and drug manufacturers and others; DAPT ClinicalTrials.gov number, NCT00977938.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For example, the reporting and interpretation of the risk of all-cause mortality in the DAPT (dual antiplatelet therapy) study randomizing 9,961 patients to continue DAPT beyond 1 y after stent placement or receive a placebo for 30 mo, raised some concerns (24, 25).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [24]
In the citing paper
“Large observational studies or head-to-head RCTs show similar rates of gastrointestinal and non-gastrointestinal major bleeding for single antiplatelet therapy (SAPT) with low-dose ASA or a P2Y 12 inhibitor (clopidogrel or ticagrelor).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Regarding CV safety, the composite of MI, stroke, CV death, CHD, and acute limb ischaemia was similar between pantoprazole and placebo, as was the rate of new-onset diabetes.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Thus, gastrointestinal mucosal bleeding appears to be due to pre-existing mucosal lesions associated with defective primary haemostasis secondary to platelet inhibition, rather than with a specific antiplatelet drug.”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
In the citing paper
“Combined antithrombotic drugs, while effective, increase major bleeding risk.337,338”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [337]
Citations
Cites
Statistical Analysis With Missing Data
Lahiff, M., Little, R. J. A., & Rubin, D. B. (1989) · Journal of the American Statistical Association · doi:10.2307/2289883 · Cited by 17,265
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Anderson, C. A. M., Arora, P., Avery, C. L., Baker-Smith, C. M., Beaton, A. Z., Boehme, A. K., Buxton, A. E., et al. (2023) · Circulation · doi:10.1161/cir.0000000000001123 · Cited by 8,300
Ticagrelor versus clopidogrel in patients with acute coronary syndromes
Wallentin, L., Becker, R. C., Budaj, A., Cannon, C. P., Emanuelsson, H., Held, C., Horrow, J., Husted, S., James, S., Katus, H., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904327 · Cited by 7,117
Self-citationPrasugrel versus clopidogrel in patients with acute coronary syndromes
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706482 · Cited by 6,790
Self-citation(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Clinical End Points in Coronary Stent Trials: A Case for Standardized Definitions
Cutlip, D. E., Windecker, S., Mehran, R., Boam, A., Cohen, D. J., van Es, G.-A., Gabriel Steg, P., Morel, M.-A., Mauri, L., Vranckx, P., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.685313 · Cited by 5,497
Self-citationHeart Disease and Stroke Statistics—2013 Update: A Report From the American Heart Association
Go, A. S., Mozaffarian, D., Roger, V. L., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., Fox, C. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828124ad · Cited by 5,292
Mehran, R., Rao, S. V., Bhatt, D. L., Gibson, C. M., Caixeta, A., Eikelboom, J., Kaul, S., Wiviott, S. D., Menon, V., Nikolsky, E., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.009449 · Cited by 4,476
Self-citation(2014) · European Heart Journal · doi:10.1093/eurheartj/ehu278 · Cited by 4,314
Research works printed but not linked: 1
- Feres F, 2013, JAMA, 310, 2510
Cited by
Items 801–900 of 1,001
Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes
Sidhu, M. S., Lyubarova, R., Bangalore, S., & Bonaca, M. P. (2021) · American Heart Journal · doi:10.1016/j.ahj.2021.12.005 · Cited by 10
Current Perspectives on Antithrombotic Therapy for the Treatment of Acute Coronary Syndrome
Towashiraporn, K., & Krittayaphong, R. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s289295 · Cited by 10
“However, the 2 groups had similar rates of bleeding.42 The 2020 NSTE-ACS guidelines suggest the use of prasugrel in preference to ticagrelor for patients with NSTE-ACS who are scheduled to proceed to PCI.”
MethodInfluentialOrtega‐Paz, L., Franchi, F., Rollini, F., Galli, M., Been, L. F., Ghanem, G., Shalhoub, A., Ossi, T., Rivas, A., Zhou, X., et al. (2023) · Thrombosis and Haemostasis · doi:10.1055/a-2098-6639 · Cited by 10
Mihatov, N., Kirtane, A. J., Stoler, R., Feldman, R., Neumann, F., Boutis, L., Tahirkheli, N. K., Kereiakes, D. J., Töelg, R., Othman, I., et al. (2023) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2023.06.036 · Cited by 10
Self-citationAgbaedeng, T. A., Noubiap, J. J., Roberts, K. A., Chew, D. P., Psaltis, P. J., & Amare, A. T. (2024) · Drugs · doi:10.1007/s40265-024-02034-3 · Cited by 10
Making headway in anticoagulant and antiplatelet therapy
Fareed, J. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.222 · Cited by 10
Liou, K., Nagaraja, V., Jepson, N. S., & Ooi, S. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.03.073 · Cited by 10
Hernández, J. M. D. L. T., Domínguez, J. F. O., Hernández, F., Camarero, T. G., Altisent, O. A., Crespo, F. R., Cascón, J. D., Zavala, G., Gimeno, F., Moreno, A. L. A., et al. (2015) · Revista Española de Cardiología · doi:10.1016/j.recesp.2015.01.010 · Cited by 10
Long-Term P2Y12-Receptor Antagonists in Post-Myocardial Infarction Patients
Alexopoulos, D. K., Xanthopoulou, I., Μούλιας, Α., & Lekakis, J. P. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.05.088 · Cited by 12
Kim, C., Han, J., Yang, H., Park, K. W., Lee, H., Kang, H., Koo, B., Lee, N., Cha, T., Yang, T., et al. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016617 · Cited by 10
Song, Y. B., Oh, S. K., Oh, J. H., Im, E. S., Cho, D., Cho, B. R., Lee, J., Lee, J. M., Park, T. K., Yang, J. H., et al. (2017) · American Heart Journal · doi:10.1016/j.ahj.2017.12.002 · Cited by 10
Wang, J., Guan, C., Qiao, S., Cao, X., Qin, L., Li, Y., Li, Z., Li, X., Yuan, J., Gao, R., et al. (2018) · EuroIntervention · doi:10.4244/eij-d-17-00946 · Cited by 10
Navarese, E. P., Kołodziejczak, M. M., Petrescu, A. M., Wernly, B., Lichtenauer, M., Lauten, A., Buffon, A., Wańha, W., Pestrichella, V., Sardella, G., et al. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1474099 · Cited by 10
“Given the relevance of additional anti-ischemic and potential antiplatelet mechanisms provided by the PCSK9 inhibitors, a subject of future investigation is to test whether this therapy might serve as antithrombotic therapy without consequent effect on bleeding complications that might allow ultimately for possible sh…”
BackgroundInfluentialUeshima, D., Yoshikawa, S., Sasaoka, T., Hatano, Y., Kurihara, K., Maejima, Y., Isobe, M., & Ashikaga, T. (2018) · Internal Medicine · doi:10.2169/internalmedicine.1553-18 · Cited by 10
“coronary intervention (PCI) has been controversial, especially with regard to the types of medicines and duration of treatment in patients receiving antithrombotic therapy (17-19).”
BackgroundSherwood, M. W., & Vora, A. N. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-1073-9 · Cited by 10
Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions
Markel, K. M., & Avgerinos, E. D. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190101111123 · Cited by 10
Sharma, A., Deyell, J., Sharma, S. N., & Barseghian, A. (2019) · Current Cardiology Reports · doi:10.1007/s11886-019-1168-y · Cited by 10
Sim, D. S., Jeong, M. H., Kim, H.-S., Gwon, H., Seung, K. B., Rha, S., Chae, S. C., Kim, C. J., Cha, K. S., Park, J., et al. (2019) · Journal of Cardiology · doi:10.1016/j.jjcc.2019.06.006 · Cited by 10
Patel, D. B., Shah, R. M., & Jovin, I. S. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.11.17 · Cited by 13
Wang, H., Dou, K., Yin, D., Xu, B., Zhang, D., & Gao, R.-L. (2020) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2020.07.033 · Cited by 10
Zheng, W., Zhang, Y.-J., Liu, R., Zhao, X., & Ai, H. (2020) · Medicine · doi:10.1097/md.0000000000021312 · Cited by 12
“However, this may increase the risk of bleeding and is linearly related to the duration of DAPT treatment.([4]) Studies showed that major bleeding after PCI was associated with increased mortality.”
BackgroundChang, C., Tung, Y., Liu, J., Chang, S., Kuo, C.-T., & See, L. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2011 · Cited by 10
Kedhi, E., Verdoia, M., Suryapranata, H., Damen, S. A. J., Camaro, C., Benit, E., Barbieri, L., Rasoul, S., Liew, H. B., Polad, J., et al. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.02.006 · Cited by 10
Ferreira, J. P., Cleland, J. G. F., Lam, C. S. P., Anker, S. D., Mehra, M. R., van Veldhuisen, D. J., Byra, W. M., Police, D. A. L., Greenberg, B., & Zannad, F. M. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01891-2 · Cited by 10
Tam, C. C., & Tse, H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11247440 · Cited by 10
“DAPT [43] All-cause death, MI, stroke 4.”
BackgroundKline, K. P., Conti, C. R., & Winchester, D. E. (2015) · Postgraduate Medicine · doi:10.1080/00325481.2015.1092374 · Cited by 12
“Duration of therapy after ACS is typically at least 1 year; however, there is currently divergent evidence and disagreement on the benefit of longer duration dual antiplatelet therapy [42-44].”
BackgroundVarenne, O., Cuisset, T., Chaïb, A., Morice, M., Sabaté, M., Koh, T., Durand‐Zaleski, I., Hanon, O., Bogaerts, K., & Sinnaeve, P. (2017) · EuroIntervention · doi:10.4244/eijy15m12_02 · Cited by 10
Otsuki, S., Brugaletta, S., Sabaté, M., Shiratori, Y., Gómez-Monterrosas, O., Scalone, G., Romero-Villafañe, S., Hernández‐Enríquez, M., Freixa, X., Martín‐Yuste, V., et al. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.02.006 · Cited by 10
“The majority of those trials may be however penalized from the fact to newer-generation DES together with first-generation DES, likely diluting the beneficial effect of a short DAT over a long DAT [45–48].”
BackgroundStolker, J. M., Cohen, D. J., Kennedy, K. F., Pencina, M. J., Arnold, S. V., Kleiman, N. S., & Spertus, J. A. (2016) · Cardiovascular revascularization medicine · doi:10.1016/j.carrev.2016.12.014 · Cited by 10
Self-citationLi, J., Ju, J., Chen, Z., Liu, J., Lu, F. Y., Gao, R., & Xu, H. (2018) · Trials · doi:10.1186/s13063-017-2373-x · Cited by 10
“For example, in the DAPT trial [9], researchers found that 30 months of DAPT led to a 0.”
BackgroundMethodWang, X., Pei, C., Bai, Y., Dai, Q., Deng, X., Liu, Y., Li, Z., You, J., Peng, J., Li, L., et al. (2018) · Angiology · doi:10.1177/0003319718804661 · Cited by 10
Antiplatelet Agents for Cancer Prevention: Current Evidences and Continuing Controversies
Frère, C., Lejeune, M., Kubicek, P., Faille, D., Marjanovic, Z., & Cancer, T. G. F. T. E. (2019) · Cancers · doi:10.3390/cancers11111639 · Cited by 10
“02) [88], suggesting that DAPT should be limited to 1–2 years to avoid the potential risk of new cancers.”
BackgroundYoon, Y., Ahn, J., Kang, D., Park, H., Cho, S., Lee, P. H., Hur, S., Kim, W., Park, C. S., Lee, B., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.03.019 · Cited by 10
Complexity of Antiplatelet Therapy in Coronary Artery Disease Patients
Sabouret, P. F., Savage, M. P., Fischman, D. L., & Costa, F. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00414-0 · Cited by 11
Xulu, K. R., & Augustine, T. N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084153 · Cited by 10
“These findings thus support studies that have shown that combined hormone and antiplatelet therapy may promote tumour survival [40,41,43,76,77].”
ResultP2Y12 blocker monotherapy after percutaneous coronary intervention
Verheugt, F. W. A., Damman, P., Damen, S. A. J., Wykrzykowska, J. J., Woelders, E. C. I., & van Geuns, R. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01582-7 · Cited by 10
Lee, J. M., Cho, D., Hahn, J., Song, Y. B., Park, T. K., Oh, J.-H., Lee, J. B., Doh, J., Kim, S., Yang, J. H., et al. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.07.022 · Cited by 10
Butala, N. M., Jaffer, F. A., & Sabatine, M. S. (2020) · Springer eBooks · doi:10.1007/978-3-030-45792-1_4 · Cited by 10
The Optimal Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation
Price, M. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.004 · Cited by 10
“” With this sobering admonition regarding the practical implications of adopting extended P2Y12 inhibition in the current era of second-generation DES, the investigators cast doubt on the appropriate application of the DAPT trial findings, in which the risk reduction in ischemic events beyond 1 year of thienopyridine…”
InfluentialNebiolo, M., Kang, J., Sandrone, S., Kim, H. K., Mattesini, A., Lee, S. Y., Piccolo, R., Lim, Y., Perl, L., Youn, Y. J., et al. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133542 · Cited by 9
Antiplatelet Therapy in Heart Disease
Özyüncü, N. (2025) · Reviews in Cardiovascular Medicine · doi:10.31083/rcm36522 · Cited by 11
“The DAPT score can help differentiate patients more likely to benefit from extended DAPT regimens, while minimizing bleeding risk [92].”
Greco, A., & Capodanno, D. (2025) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd12090344 · Cited by 12
“It includes nine variables (i.e., age, smoking, diabetes, MI at presentation, prior PCI or MI, use of paclitaxel-eluting stent, stent diameter 3 mm, heart failure or left ventricular ejection fraction 30%, and vein graft PCI), with scores ≥ 2 indicating net benefit from prolonged DAPT [125].”
InfluentialCaneiro‐Queija, B., Abu‐Assi, E., Raposeiras‐Roubín, S., Manzano‐Fernández, S., Flores‐Blanco, P. J., López‐Cuenca, Á., Paz, R. C., Gómez-Molina, M., Rodríguez-Rodríguez, J. M., Calvo, F., et al. (2018) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.02.005 · Cited by 9
“IMC 27,9 [25,4-31,1] 28,1 [25,4-31,3] 27,9 [25,4-31,1] 0,57 28,1 [25,5-31,0] 27,9 [25,3-31,1] 0,94”
Improving the Design of Future PCI Trials for Stable Coronary Artery Disease
Marquis‐Gravel, G., Moliterno, D. J., Francis, D. P., Jüni, P., Rosenberg, Y., Claessen, B. E. P. M., Mentz, R. J., Mehran, R., Cutlip, D. E., Chauhan, C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.05.060 · Cited by 10
Self-citationThiele, H., Bauersachs, J. K., Mehilli, J., Möllmann, H., Landmesser, U., & Jobs, A. (2021) · Der Kardiologe · doi:10.1007/s12181-020-00442-9 · Cited by 15
Huard, K., Haddad, K., Saada, Y., Nguyen, J., Banon, D., Matteau, A., Mansour, S., & Potter, B. J. (2022) · Scientific Reports · doi:10.1038/s41598-022-17034-0 · Cited by 9
Yan, K., Zhu, P., Tang, X., Li, Y., Li, J., Yuan, D., Yang, W., Yang, Y., Gao, R., Xu, B., et al. (2023) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.64212 · Cited by 9
Risks and benefits of extended DAPT after stenting
Huynh, K. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.192 · Cited by 9
Sharma, A., Lavie, C. J., Sharma, S. K., Garg, A., Vallakati, A., Mukherjee, D., & Marmur, J. D. (2016) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.06.004 · Cited by 9
Bioresorbable Vascular Scaffold During ST-Elevation Myocardial Infarction: A Systematic Review
Picard, F. A., de Hemptinne, Q., Avram, R., Ly, H. Q., L’Allier, P. L., & Tanguay, J. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.11.022 · Cited by 9
Kolandaivelu, K., Bailey, L. R., Buzzi, S., Zucker, A., Milleret, V., Ziogas, A., Ehrbar, M., Khattab, A. A., Stanley, J. R. L., Wong, G. K., et al. (2017) · EuroIntervention · doi:10.4244/eij-d-15-00497 · Cited by 9
Essandoh, M. K., Dalia, A. A., Albaghdadi, M. S., George, B., Stoicea, N., Shabsigh, M., & Rao, S. V. (2017) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.04.046 · Cited by 9
“Multiple large, randomized clinical trials have investigated the mandatory duration of DAPT following second-generation metallic DES-PCI, and the outcomes of these studies influenced the 2016 ACC/AHA guideline (10, 12, 16-26).”
BackgroundEsposti, L. D., Perrone, V., Veronesi, C., Buda, S., & Rossini, R. (2018) · Vascular Health and Risk Management · doi:10.2147/vhrm.s162004 · Cited by 9
Chen, W. W. C., Law, K., Li, S.-K., Chan, W. C. K., Cheong, A., Fong, P., Hung, Y., Lai, S. W. K., Leung, G. T.-C., Wong, E., et al. (2019) · Internal Medicine Journal · doi:10.1111/imj.14153 · Cited by 12
Deharo, P., & Cuisset, T. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.05.008 · Cited by 9
“he prolongation of aspirin plus a thienopyridine at 12 months of CS versus thienopyridine cessation [28] .”
BackgroundMethodDual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin?
Ziada, K. M., & Moliterno, D. J. (2019) · JAMA · doi:10.1001/jama.2019.7025 · Cited by 9
Dobesh, P. P., Finks, S. W., & Trujillo, T. C. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.08.003 · Cited by 9
Ueda, Y., Kosugi, S., Abe, H., Ozaki, T., Mishima, T., Date, M., Uematsu, M., & Koretsune, Y. (2020) · Journal of Cardiology · doi:10.1016/j.jjcc.2020.08.007 · Cited by 9
Patient after myocardial infarction: how to reduce the risk of recurrent ischemic events?
Барбараш, О. Л., Каретникова, В. Н., & Кашталап, В. В. (2015) · Cardiosomatics · doi:10.26442/cs45109 · Cited by 10
New Possibilities to Reduce the Residual Risk in Patients with Ischemic Heart Disease
Bershtein, L. L. (2020) · Kardiologiia · doi:10.18087/cardio.2020.11.n1370 · Cited by 9
Xu, Y., Shen, Y., Chen, D., Zhao, P., & Jiang, J. (2021) · Journal of Interventional Cardiology · doi:10.1155/2021/9934535 · Cited by 9
Said, S. A., Alabed, S., Kaier, K., Bode, C., Meerpohl, J. J., & Duerschmied, D. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013252 · Cited by 9
Elliott, J., Kelly, S., Bai, Z., Skidmore, B., Boucher, M., So, D. Y. F., & Wells, G. A. (2023) · CMAJ Open · doi:10.9778/cmajo.20210119 · Cited by 11
Ariotti, S., Costa, F., & Valgimigli, M. (2015) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000185 · Cited by 9
Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention
Majithia, A., & Bhatt, D. L. (2016) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2016.08.003 · Cited by 9
Dual Antiplatelet Therapy Continuation Beyond 1 Year After Drug-Eluting Stents
Ferrante, G., Condorelli, G., Pagnotta, P. A., & Reimers, B. (2017) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.116.004139 · Cited by 9
Clopidogrel reloading for patients with acute myocardial infarction already on clopidogrel therapy
Doll, J. A., Li, S., Chiswell, K., Roe, M. T., Kosiborod, M., Scirica, B. M., & Wang, T. Y. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx255 · Cited by 9
“9% among patients presenting with STEMI and NSTEMI respectively, and remained stable throughout our study period, though these rates may increase in the future due to recent trial results demonstrating benefit of prolonged dual antiplatelet therapy.(13,14) Patients on pre-admission clopidogrel may be at higher risk of…”
ResultIm, E., Cho, Y., Suh, Y., Cho, D., Her, A., Kim, Y. H., Lee, K., Kang, W. C., Yun, K. H., Yoo, S., et al. (2017) · Revista Española de Cardiología · doi:10.1016/j.recesp.2017.05.028 · Cited by 9
“Arteria descendente anterior izquierda 626 (50,2) 614 (49,3) Arteria circunfleja izquierda 247 (19,8) 245 (19,7)”
BackgroundInfluentialEsquivel, D. V., Bátiz-Armenta, F., Cazares-Diazleal, A. C., Oviedo-Moguel, S., Jarvio-Fernandez, S. M., Arce-Gonzalez, J. M., & Ivey-Miranda, J. B. (2018) · Hellenic Journal of Cardiology · doi:10.1016/j.hjc.2018.05.007 · Cited by 9
Bhagirath, V. C., Eikelboom, J. W., & Anand, S. S. (2018) · Future Cardiology · doi:10.2217/fca-2018-0059 · Cited by 9
Piranavan, P., Kaur, N. J., Marmoush, F. Y., Burton, A., & Hannan, J. C. (2018) · Cureus · doi:10.7759/cureus.3720 · Cited by 9
Is P2Y12 inhibitor therapy associated with an increased risk of cancer?
Kaufmann, C. C., Lyon, A. R., Wojta, J., & Huber, K. (2019) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvz003 · Cited by 9
Lauver, A. A., Kuszynski, D. S., Christian, B., Bernard, M. P., Teuber, J. P., Markham, B. E., Chen, Y. E., & Zhang, H. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.509 · Cited by 9
Mureddu, G. F., Greco, C., Rosato, S., D’Errigo, P., Luca, L. D., Badoni, G., Faggiano, P. M., & Seccareccia, F. (2019) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2019.1166 · Cited by 9
“According to diagnostic criteria used in previous epidemiological [11] and clinical studies [12,13] patients were classified as having high thrombotic risk (HTR) on the basis of the presence of at least one of the following characteristics recorded either in the index admission or in the previous 5-year hospitalizatio…”
BackgroundMethodResultXu, J., Song, Y., Gao, Z., Jiang, P. X., Liu, R., Wang, H., Qiao, S., Gao, R., Yang, Y., Xu, B., et al. (2019) · Platelets · doi:10.1080/09537104.2019.1693036 · Cited by 10
Dual Antiplatelet Therapy in Patients with High Cardiovascular Risk
Espinoza, C., & Mukherjee, D. (2021) · Heart International · doi:10.17925/hi.2021.15.1.26 · Cited by 9
Calderone, D., Ingala, S., Mauro, M. S., Angiolillo, D. J., & Capodanno, D. (2021) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2021.2020100 · Cited by 11
“All-cause and cardiovascular mortality were similar between the two groups [78].”
BackgroundMethodPalla, M., Briasoulis, Α., Siddiqui, F., Alesh, I. G., & Afonso, L. (2015) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000000307 · Cited by 9
Bleeding risk associated with eptifibatide (Integrilin) bridging in thoracic surgery patients
Waldron, N. H., Dallas, T., Erhunmwunsee, L., Wang, T. Y., Berry, M. F., & Welsby, I. J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-016-1441-5 · Cited by 9
“While DAPT is efficacious for the prevention of stent thrombosis and MACE, it increases bleeding risk [9].”
Dual-antiplatelet Therapy Guidelines and Implications for Perioperative Management
Stawiarski, K. M., Kataria, R., Bravo, C., Villablanca, P., Mohananey, D., Narasimhan, S., & Ramakrishna, H. (2017) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2017.06.033 · Cited by 10
Li, K.-C., Yu, S., & Zhuge, B. (2017) · Medicine · doi:10.1097/md.0000000000007566 · Cited by 9
“Dual antiplatelet therapy (DAT) with aspirin and clopidogrel is a commonly recommended treatment used to prevent adverse cardiovascular events in patients suffering from CHD after stent implantation.([1,2]) Unfortunately, this treatment regimen still fails to produce good antiplatelet effects in some patients, leading…”
BackgroundVerdoia, M., Camaro, C., Kedhi, E., Marcolongo, M., Suryapranata, H., & Luca, G. D. (2020) · Cardiovascular Therapeutics · doi:10.1155/2020/6495036 · Cited by 9
“In the Dual Antiplatelet ,erapy (DAPT) trial [40], a total of 9961 patients undergoing DES implantation were randomly assigned at 1-year follow-up to continue thienopyridine treatment up to 30 months or to receive placebo.”
BackgroundDual Antiplatelet Therapy Duration Following Coronary Stenting ∗
Yeh, R. W., Mauri, L., & Kereiakes, D. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.01.004 · Cited by 9
“Food and Drug Administration, is adequately powered for the efficacy coprimary endpoints of ST (Academic Research Consortium definite/probable definition) and major adverse cardiovascular and cerebrovascular events (composite occurrence of death, MI or stroke), as well as a primary safety endpoint of severe/moderate (…”
Self-citationThe long journey of individualizing antiplatelet therapy after acute coronary syndromes
Storey, R. F. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa644 · Cited by 9
Antiplatelet therapy for treatment of coronary artery disease in older patients
Fischer, Q., Pham, V., Seret, G., Brami, P., Picard, F. A., & Varenne, O. (2024) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2024.02.008 · Cited by 8
Joseph, M., Krishna, M. M., Ezenna, C. G., Pereira, V., Ismayl, M., Nanna, M. G., Bangalore, S., & Goldsweig, A. M. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.10.038 · Cited by 8
Radišauskas, R., Šileikienė, L., Krančiukaitė-Butylkinienė, D., Augustis, Š., Jasukaitienė, E., Lukšienė, D., Tamošiūnas, A., Marcinkevičienė, K., Virvičiūtė, D., Žaliaduonytė, D., et al. (2025) · Medicina · doi:10.3390/medicina61050910 · Cited by 8
“First, the incidence of AMI has decreased in various populations since the middle of the last century [18,45] due to a decrease in the prevalence of atherosclerotic CVD risk factors and the implementation of modern primary and secondary CVD prevention strategies [46,47].”
Duration of dual antiplatelet therapy after various drug-eluting stent implantation
Sharma, A., Sharma, S. K., Vallakati, A., Garg, A., Lavie, C. J., Mukherjee, D., & Marmur, J. D. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.04.118 · Cited by 8
Nicholls, S. J., & Nelson, A. J. (2019) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-00322-4 · Cited by 8
Chronic Coronary Syndrome: Overcoming Clinical Practice Guidelines. The role of the COMPASS Strategy
Arribas, F., Barrios, V., Amaro, M. B., Martí‐Almor, J., Martínez, J. G., Duque, J. A. A., Ortiz, M. R., Vázquez, R., & Valle, A. (2020) · Current Cardiology Reviews · doi:10.2174/1573403x16999200817111150 · Cited by 8
“5 mg bid to aspirin has demonstrated to have a positive impact not only on MACE, but also on mortality as a secondary end-point [5, 8-16].”
BackgroundResultAntiplatelet therapy for coronary artery disease in 2023: current status and future prospects
Chandiramani, R., Spirito, A., Johnson, J. W., Mehta, A., Vogel, B., FAILLACE, R. T., & Mehran, R. (2023) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2023.2201437 · Cited by 8
“Among 9961 patients receiving 12 months of DAPT with no major ischemic or bleeding events, those assigned to DAPT (aspirin plus thienopyridine) for an additional 18 months were found to have significantly lower rates of stent thrombosis as well as the co-primary ischemic composite endpoint (death, MI or stroke) albeit…”
BackgroundSpirito, A., Cao, D., Sartori, S., Sharma, A., Smith, K. F., Vogel, B., Kamaleldin, K. M., Koshy, A. N., Feng, Y., Power, D., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad069 · Cited by 8
Abe, T., Nagai, T., Yuasa, A., Tokuda, Y., Ishizaka, S., Takenaka, S., Mizuguchi, Y., Nakao, M., Sato, T., Temma, T., et al. (2024) · Cardiovascular Intervention and Therapeutics · doi:10.1007/s12928-024-01043-z · Cited by 8
“The primary outcome of interest was major adverse cardiac and cerebrovascular events (MACCE) including all-cause death, myocardial infarction and stroke according to a representative randomized clinical trial [15].”
Hernández, J. M. D. L. T., Domínguez, J. F. O., Hernández, F., Camarero, T. G., Altisent, O. A., Crespo, F. R., Cascón, J. D., Zavala, G., Gimeno, F., Moreno, A. L. A., et al. (2015) · Revista Española de Cardiología (English Edition) · doi:10.1016/j.rec.2015.01.008 · Cited by 8
Patti, G., & Cavallari, I. (2016) · American Heart Journal · doi:10.1016/j.ahj.2016.03.005 · Cited by 8
Zeymer, U., Becher, A., Jennings, E., Johansson, S., & Westergaard, M. (2016) · European Heart Journal Acute Cardiovascular Care · doi:10.1177/2048872616648467 · Cited by 8
Nallu, K., Makker, P., Behuria, S., Fox, J., & Kanei, Y. (2016) · International Journal of Angiology · doi:10.1055/s-0036-1593828 · Cited by 8
Wang, W., Liu, J., Fang, J., Liu, Y., An, T., Zou, M., & Cheng, G. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.02.091 · Cited by 8
“First, with the exception for two trials [9,20], the majority of trials had an open-label design potentially introducing a bias.”
BackgroundMethodInfluentialFukamachi, D., Hirayama, A., Miyauchi, K., Yasuda, S., Ogawa, H., Ito, H., & Daida, H. (2018) · Journal of Cardiology · doi:10.1016/j.jjcc.2018.01.017 · Cited by 9
Cordonnier, C., Lemesle, G., Casolla, B., Bic, M., Caparros, F., Lamblin, N., & Bauters, C. (2018) · European Stroke Journal · doi:10.1177/2396987318772684 · Cited by 9
Metadata
- Authors
- Mauri, L., Kereiakes, D. J., Yeh, R. W., Driscoll-Shempp, P., Cutlip, D. E., Steg, P. G., Normand, S.-L. T., Braunwald, E., Wiviott, S. D., Cohen, D. J., Holmes, D. R., Krucoff, M. W., Hermiller, J., Dauerman, H. L., Simon, D. I., Kandzari, D. E., Garratt, K. N., Lee, D. P., Pow, T. K., Ver Lee, P., Rinaldi, M. J., & Massaro, J. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Christ Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- University of Missouri–Kansas City (US)
- Duke Medical Center (US)
- St Vincent Hospital (US)
- University of Vermont (US)
- University Hospitals Cleveland Medical Center (US)
- Piedmont Atlanta Hospital (US)
- Lenox Hill Hospital (US)
- Stanford University (US)
- Carolinas Healthcare System (US)
- Boston University (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-12-04
- Volume
- 371
- Issue
- 23
- Pages
- 2155-2166
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481318
- OpenAlex
- W2125173296
- Cited by
- 1,928
- References
- 39
- Citations by year
- 2026: 69 · 2025: 75 · 2024: 80 · 2023: 109 · 2022: 125 · 2021: 154 · 2020: 182 · 2019: 150 · 2018: 183 · 2017: 242 · 2016: 288 · 2015: 254 · 2014: 9
- FWCI
- 181.65
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- BORIS (University Library Bern) (submittedVersion, other-oa)
- Open Access CRIS of the University of Bern
- Funders
- U.S. Food and Drug Administration (1r01fd003870-01, R01 FD003870)
- National Heart, Lung, and Blood Institute (R01HL057506, R37HL057506, K23HL118138)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- dual antiplatelet therapy, drug-eluting stents, coronary stenting, clopidogrel, prasugrel, thienopyridines, aspirin, stent thrombosis, major adverse cardiovascular events, bleeding risk, myocardial infarction, stroke, mortality, periprocedural bleeding, bleeding risk stratification
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Drug Administration Schedule, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Piperazines, Platelet Aggregation Inhibitors, Thiophenes, Thrombosis, Ticlopidine, Time Factors, Incidence, Myocardial Ischemia, Drug-Eluting Stents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.